Ping Li1, Mei Zhang, Wen-Jing Ma, Xin Sun, Fu-Peng Jin. 1. Department of Traditional Chinese Medicine Oncology, Provincial Hospital of Anhui Medical University, Hefei 230001, China.
Abstract
OBJECTIVE: To study the effects of brucine on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) in a nude mouse model of bone metastasis due to breast cancer, and to assess the possible antitumor mechanism of brucine. METHODS: A syringe needle was used to directly inject 0.2 mL monoplast suspension (with 2×10(5) human breast cancer cells contained) into the bony femoral cortex of the right hind leg for modeling. Twenty-five nude mice were randomized into five groups and administered with an intraperitoneal injection of saline or drug for 8 consecutive days: model group (0.2 mL normal saline), low-dose brucine group (1.73 mg·kg(-1)), medium-dose brucine group (3.45 mg·kg(-1)), high-dose brucine group (6.90 mg·kg(-1)), and thalidomide group (200 mg·kg(-1)). Diet and activity were recorded, and the tumors were harvested 5 weeks later. The percentage of VEGF-positive cells was determined with hematoxylin and eosin staining and immunohistochemical staining, and MVD expression was determined by optical microscopy. RESULTS: The VEGF expressions in brucine- or thalidomide-treated mice were significantly reduced as compared with mice in the model group (P <0.01). There were no significant difference between the high-dose brucine group and the thalidomide group (P >0.05). Significant difference was between the high- and low-dose brucine group P<0.05). Further, VEGF expression was significantly increased in the low- and medium-dose brucine groups compared with the thalidomide group (P <0.05). The MVD values in the three brucine and thalidomide groups were significantly lower than that in the model group (P <0.01). The MVD values in the medium- and high-dose brucine groups were not significantly different from those in the thalidomide group (P >0.05), while the MVD value showed a significant increase in the low-dose group compared with the thalidomide group (P <0.05). CONCLUSION: Brucine could inhibit the growth of breast cancer to bone metastases, possibly by inhibiting tumor angiogenesis.
OBJECTIVE: To study the effects of brucine on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) in a nude mouse model of bone metastasis due to breast cancer, and to assess the possible antitumor mechanism of brucine. METHODS: A syringe needle was used to directly inject 0.2 mL monoplast suspension (with 2×10(5) humanbreast cancer cells contained) into the bony femoral cortex of the right hind leg for modeling. Twenty-five nude mice were randomized into five groups and administered with an intraperitoneal injection of saline or drug for 8 consecutive days: model group (0.2 mL normal saline), low-dose brucine group (1.73 mg·kg(-1)), medium-dose brucine group (3.45 mg·kg(-1)), high-dose brucine group (6.90 mg·kg(-1)), and thalidomide group (200 mg·kg(-1)). Diet and activity were recorded, and the tumors were harvested 5 weeks later. The percentage of VEGF-positive cells was determined with hematoxylin and eosin staining and immunohistochemical staining, and MVD expression was determined by optical microscopy. RESULTS: The VEGF expressions in brucine- or thalidomide-treated mice were significantly reduced as compared with mice in the model group (P <0.01). There were no significant difference between the high-dose brucine group and the thalidomide group (P >0.05). Significant difference was between the high- and low-dose brucine group P<0.05). Further, VEGF expression was significantly increased in the low- and medium-dose brucine groups compared with the thalidomide group (P <0.05). The MVD values in the three brucine and thalidomide groups were significantly lower than that in the model group (P <0.01). The MVD values in the medium- and high-dose brucine groups were not significantly different from those in the thalidomide group (P >0.05), while the MVD value showed a significant increase in the low-dose group compared with the thalidomide group (P <0.05). CONCLUSION:Brucine could inhibit the growth of breast cancer to bone metastases, possibly by inhibiting tumor angiogenesis.
Authors: Ulka N Vaishampayan; Lance K Heilbrun; Anthony F Shields; Jawana Lawhorn-Crews; Karen Baranowski; Daryn Smith; Lawrence E Flaherty Journal: Invest New Drugs Date: 2006-08-26 Impact factor: 3.850
Authors: Eleni Efstathiou; Patricia Troncoso; Sijin Wen; Kim-Anh Do; Curtis A Pettaway; Louis L Pisters; Timothy J McDonnell; Christopher J Logothetis Journal: Clin Cancer Res Date: 2007-02-15 Impact factor: 12.531
Authors: I J Diel; J-J Body; M R Lichinitser; E D Kreuser; W Dornoff; V A Gorbunova; M Budde; B Bergström Journal: Eur J Cancer Date: 2004-07 Impact factor: 9.162
Authors: Nabil A Alhakamy; Hibah M Aldawsari; Javed Ali; Dipak K Gupta; Musarrat H Warsi; Anwar L Bilgrami; Hani Z Asfour; Ahmad O Noor; Shadab Md Journal: 3 Biotech Date: 2021-05-22 Impact factor: 2.893